419 related articles for article (PubMed ID: 24186263)
1. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
4. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Derungs A; Donzelli M; Berger B; Noppen C; Krähenbühl S; Haschke M
Clin Pharmacokinet; 2016 Jan; 55(1):79-91. PubMed ID: 26123704
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation.
Peng Y; Wu H; Zhang X; Zhang F; Qi H; Zhong Y; Wang Y; Sang H; Wang G; Sun J
Xenobiotica; 2015; 45(11):961-77. PubMed ID: 26007223
[TBL] [Abstract][Full Text] [Related]
8. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
9. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
[TBL] [Abstract][Full Text] [Related]
10. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.
Sane RS; Ramsden D; Sabo JP; Cooper C; Rowland L; Ting N; Whitcher-Johnstone A; Tweedie DJ
Drug Metab Dispos; 2016 Mar; 44(3):466-75. PubMed ID: 26684498
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
13. An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes.
Custodio JM; Donaldson KM; Hunt HJ
J Clin Pharmacol; 2021 Feb; 61(2):244-253. PubMed ID: 32869328
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
[TBL] [Abstract][Full Text] [Related]
15. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity.
Kahma H; Aurinsalo L; Neuvonen M; Katajamäki J; Paludetto MN; Viinamäki J; Launiainen T; Filppula AM; Tornio A; Niemi M; Backman JT
Eur J Pharm Sci; 2021 Jul; 162():105810. PubMed ID: 33753217
[TBL] [Abstract][Full Text] [Related]
16. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.
Zheng L; Lu Y; Cao X; Huang Y; Liu Y; Tang L; Liao SG; Wang AM; Li YJ; Lan YY; Wang YL
J Ethnopharmacol; 2014 Dec; 158 Pt A():276-82. PubMed ID: 25446640
[TBL] [Abstract][Full Text] [Related]
18. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
Liu LY; Han YL; Zhu JH; Yu Q; Yang QJ; Lu J; Guo C
Biomed Chromatogr; 2015 Mar; 29(3):437-44. PubMed ID: 25098274
[TBL] [Abstract][Full Text] [Related]
19. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]